Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15847704 | 0.94 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL15467400 | 0.94 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL12345481 | 0.73 | — | — | |
| SCHEMBL1848624 | 0.73 | — | — | |
| SCHEMBL9877619 | 0.71 | — | — | |
| SCHEMBL112396 | 0.68 | — | — | |
| SCHEMBL21542480 | 0.63 | — | — | |
| SCHEMBL12969947 | 0.63 | — | — | |
| SCHEMBL3221560 | 0.59 | — | — | |
| SCHEMBL15467260 | 0.57 | MAPK1 (0.42) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | PURDUE PHARMA L.P. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-16 | — | — | US | disclosed |
| US-20180370971-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-12-27 | — | — | US | disclosed |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-05-31 | — | — | US | disclosed |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-05-31 | — | — | US | disclosed |
| US-9890164-B2 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | PURDUE PHARMA, L.P. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890164-B2 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | PURDUE PHARMA, L.P. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| EP-2537844-A1 | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | Purdue Pharma L.P. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2537844-A1 | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | Purdue Pharma L.P. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2324013-B1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2324013-B1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | disclosed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | disclosed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | disclosed |
| EP-2324013-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010010458-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010458-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | QDPR, P2RX4, P2RX5 | MAPK1 1874/4885 |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | MAPK1 2239/4885 |
| US-20180370971-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | P2RX4, OPRK1, QDPR | MAPK1 2476/4885 |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, OPRK1, QDPR | MAPK1 2476/4885 |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | MAPK1 2239/4885 |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | P2RX4, OPRK1, QDPR | MAPK1 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.